Table 1. Patient and tumor characteristics.
| Characteristics | Prospective cohort N = 105 | Retrospective cohort N = 187 | P value |
|---|---|---|---|
| Age—median (range) | 55 (33, 80) | 55 (28, 89) | 0.699 |
| Race—no. (%) | |||
| White | 75 (71) | 130 (72) | 0.925 |
| Black | 20 (19) | 36 (19) | |
| Other | 10 (10) | 21 (11) | |
| Tumor type—no. (%) | |||
| DCIS | 11 (10) | 29 (16) | 0.352 |
| IDC | 74 (70) | 133 (71) | |
| ILC | 7 (7) | 13 (7) | |
| IMC | 10 (10) | 8 (4) | |
| Other | 3 (3) | 4 (2) | |
| Tumor size—median (range) | 1.4 (0.4, 8) | 1.4 (0, 7.1) | 0.819 |
| Tumor grade—no. (%) | |||
| 1 | 14 (13) | 32 (18) | 0.162 |
| 2 | 65 (62) | 89 (50) | |
| 3 | 26 (25) | 57 (32) | |
| Unknown | 0 | 9 | |
| ER positive—no. (%) | 92 (88) | 158 (86) | 0.724 |
| PR positive—no. (%) | 82 (78) | 134 (73) | 0.398 |
| HER2 positive—no. (%) | 9 (10) | 20 (12) | 0.682 |
Characteristics are shown separately for the prospective cohort and for the historical control group. P values for differences between cohorts are from Wilcoxon rank sum tests comparing continuous measures and Fisher's exact test for categorical measures
DCIS ductal carcinoma in situ, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, IMC invasive mammary carcinoma, PR progesterone receptor